Skip to main
IVA

Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva S.A. (IVA) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Inventiva SA is a biopharmaceutical company focused on developing lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH), a condition lacking approved therapies, while also exploring a range of pre-clinical therapy programs. The improvement in metabolic markers, such as HbA1c and insulin resistance indices, alongside the potential for lanifibranor to provide fibrosis improvement, positions the drug favorably in the therapeutic landscape, especially as a complement to existing treatments like GLP-1s. Additionally, the company's strong revenue generation through partnerships with AbbVie and BI underpins a solid financial foundation, enhancing the potential for growth and adoption in the market as clinical results continue to support lanifibranor's efficacy.

Bears say

Inventiva SA, a biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis, is currently facing a challenging financial outlook characterized by a significant net loss of €175.9 million, equating to €1.62 per share. The primary clinical program, lanifibranor, which is in Phase III development, presents considerable risks, as any issues regarding efficacy or safety could materially harm the company’s stock performance. Furthermore, the company relies heavily on research partnerships for revenue, while the overall competitive landscape in liver disease treatments reveals disappointing results for currently approved therapies, heightening concerns over Inventiva's ability to navigate future clinical and regulatory hurdles.

Inventiva S.A. (IVA) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inventiva S.A. (IVA) Forecast

Analysts have given Inventiva S.A. (IVA) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Inventiva S.A. (IVA) has a Strong Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inventiva S.A. (IVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.